Pediatric Gastroenterology, Children's Mercy Kansas City, Kansas City, MO, USA.
Pediatric Gastroenterology, New Orleans Children's Hospital, New Orleans, LA, USA.
Trials. 2021 Feb 27;22(1):169. doi: 10.1186/s13063-021-05131-w.
Although tube feeding routinely saves the lives of children who do not eat by mouth, chronic tube feeding can be a burden to patients, caregivers, and families. Very few randomized trials exist regarding the best methods for weaning children from their feeding tubes.
The current paper describes a randomized controlled trial of an empirically supported outpatient treatment protocol for moving children from tube to oral eating called iKanEat. Specifically, we describe the methods of randomized double-blind, placebo-controlled trial which includes a 4-week course of megestrol, the only medication used in the iKanEat protocol, to determine whether the addition of megestrol results in improved child outcomes. The primary and secondary aims are to assess the safety and efficacy of megestrol as part of the iKanEat protocol. The third aim is to provide critical information about the impact of the transition from tube to oral feeding on parent stress and parent and child quality of life.
This trial will provide data regarding whether megestrol is a safe and effective component of the iKanEat tube weaning protocol, as well as important data on how the tube weaning process impacts parent stress and parent and child quality of life.
ClinicalTrials.gov NCT#03815019 . Registered on January 17, 2019.
尽管管饲通常可以挽救不能经口进食的儿童的生命,但长期管饲可能会给患者、照顾者和家庭带来负担。关于如何使儿童从喂养管中逐渐恢复经口进食,仅有极少数随机试验对此进行了探讨。
本文描述了一项名为 iKanEat 的针对门诊患者的、经实证支持的管饲脱管治疗方案的随机对照试验。具体而言,我们描述了一项随机双盲、安慰剂对照试验的方法,该试验包括为期 4 周的美曲孕酮疗程,美曲孕酮是 iKanEat 方案中唯一使用的药物,以确定添加美曲孕酮是否会改善儿童的治疗结果。主要和次要目标是评估美曲孕酮作为 iKanEat 方案一部分的安全性和疗效。第三个目标是提供关于从管饲过渡到经口进食对父母压力以及父母和儿童生活质量影响的重要信息。
这项试验将提供关于美曲孕酮是否为 iKanEat 管饲脱管方案的安全有效组成部分的数据,以及关于管饲脱管过程如何影响父母压力和父母与儿童生活质量的重要数据。
ClinicalTrials.gov NCT#03815019。于 2019 年 1 月 17 日注册。